Comparing Super High-flux and High-flux Dialyzers for Hemodialysis Patients with Sepsis and End-Stage Kidney Disease A Randomized Controlled Trial

What this Trial Is About

Researchers are evaluating the effectiveness of a super high-flux dialyzer compared to a high-flux dialyzer in patients with end-stage kidney disease ESKD who also have sepsis. The study aims to see if the super high-flux dialyzer can improve survival and sepsis outcomes by better removing cytokines, which are involved in worsening sepsis despite antibiotic treatment. This is an open-label, randomized control trial conducted at a single center. Participants with ESKD and sepsis who have high levels of interleukin-6 greater than 50 pgml are randomly assigned to receive dialysis using either a super high-flux dialyzer or a high-flux dialyzer. The dialyzers are used without reuse during the first week, and standard sepsis care including antibiotics is provided to all participants without interference from the researchers. The study plans to enroll 202 participants, evenly divided between the two groups. During the study, researchers will monitor mortality at 28 days as the primary outcome. Secondary outcomes include cardiovascular death, reduction in IL-6 levels after dialysis, length of hospital stay, ventilator-free days, and dialysis-related complications. Participants will be closely observed for complications such as intradialytic hypotension. The study duration for monitoring these outcomes is up to 28 days after treatment starts.

Comparing Super High-flux and High-flux Dialyzer Performance Among Hemodialysis Patient With Sepsis : a Randomized Control Trial